MTOR and renal cell carcinoma: In the same CheckMate-214 study, this combination was studied in a favorable-risk group with similar overall survival compared to sunitinib; this combination can be used in relapse and stage IV RCC patients as a subsequent therapy after patients have undergone TKI, VEGF or mTOR therapy [32] (Category 2A).